BIOMAT Database Logo BIOMAT Database Logo

[Immunology in internal medicine. 6. Immunotherapy in internal medicine, focussing on collagen diseases]. 1988

H Hashimoto

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D010951 Plasma Exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions. Exchange, Plasma,Exchanges, Plasma,Plasma Exchanges
D010956 Plasmapheresis Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use. Double Filtration Plasmapheresis,Therapeutic Immunoadsorption,Therapeutic Plasma Adsorption,Therapeutic Plasmapheresis,Adsorption, Therapeutic Plasma,Adsorptions, Therapeutic Plasma,Double Filtration Plasmaphereses,Filtration Plasmapheresis, Double,Immunoadsorption, Therapeutic,Plasma Adsorption, Therapeutic,Plasmaphereses,Plasmapheresis, Double Filtration,Plasmapheresis, Therapeutic,Therapeutic Immunoadsorptions,Therapeutic Plasma Adsorptions,Therapeutic Plasmaphereses
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003095 Collagen Diseases Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that "collagen" was equivalent to "connective tissue", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term "collagen diseases" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494) Collagen Disease,Disease, Collagen,Diseases, Collagen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants

Related Publications

H Hashimoto
[SYMPOSIUM ON PSYCHOSOMATIC MEDICINE AND INTERNAL MEDICINE. (6) INTERNAL DISEASES].
December 1963, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
H Hashimoto
[Immunology in internal medicine. 3. Complement and diseases].
October 1988, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
H Hashimoto
[Immunology in internal medicine. 4. Cytokines and diseases].
October 1988, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
H Hashimoto
[Immunology in internal medicine. 1. Autoantibodies and diseases].
October 1988, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
H Hashimoto
[Immunology in internal medicine. 2. Immune complexes and diseases].
October 1988, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
H Hashimoto
[Enzyme diagnosis in internal medicine and internal medicine immunology].
October 1972, Vnitrni lekarstvi,
H Hashimoto
[Collagen diseases from the aspect of internal medicine].
October 1969, Saishin igaku. Modern medicine,
H Hashimoto
Integration of immunology in internal medicine.
November 1973, Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg,
H Hashimoto
[Endocrinology and Immunology -- Interrelations in internal medicine].
June 1979, Immunitat und Infektion,
H Hashimoto
[Enzymological diagnosis and immunology in internal medicine].
January 1972, Casopis lekaru ceskych,
Copied contents to your clipboard!